JP2022519764A - 二環式スルホンアミド - Google Patents

二環式スルホンアミド Download PDF

Info

Publication number
JP2022519764A
JP2022519764A JP2021547374A JP2021547374A JP2022519764A JP 2022519764 A JP2022519764 A JP 2022519764A JP 2021547374 A JP2021547374 A JP 2021547374A JP 2021547374 A JP2021547374 A JP 2021547374A JP 2022519764 A JP2022519764 A JP 2022519764A
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutically acceptable
acceptable salt
compound according
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519764A5 (https=
Inventor
レオニド ベイゲルマン
デヴィッド バーナード スミス
Original Assignee
アリゴス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゴス セラピューティクス インコーポレイテッド filed Critical アリゴス セラピューティクス インコーポレイテッド
Publication of JP2022519764A publication Critical patent/JP2022519764A/ja
Publication of JP2022519764A5 publication Critical patent/JP2022519764A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021547374A 2019-02-14 2020-02-12 二環式スルホンアミド Pending JP2022519764A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805725P 2019-02-14 2019-02-14
US62/805,725 2019-02-14
PCT/US2020/017974 WO2020167984A1 (en) 2019-02-14 2020-02-12 Bicyclic sulfonamides

Publications (2)

Publication Number Publication Date
JP2022519764A true JP2022519764A (ja) 2022-03-24
JP2022519764A5 JP2022519764A5 (https=) 2023-02-21

Family

ID=72045615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547374A Pending JP2022519764A (ja) 2019-02-14 2020-02-12 二環式スルホンアミド

Country Status (13)

Country Link
US (1) US11033556B2 (https=)
EP (1) EP3924357A4 (https=)
JP (1) JP2022519764A (https=)
KR (1) KR20210126636A (https=)
CN (1) CN113423712A (https=)
AU (1) AU2020221839B2 (https=)
BR (1) BR112021015864A2 (https=)
CA (1) CA3128061A1 (https=)
IL (1) IL284940A (https=)
MX (1) MX2021009717A (https=)
SG (1) SG11202108835SA (https=)
TW (1) TW202045516A (https=)
WO (1) WO2020167984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
EP4399217A2 (en) 2021-09-08 2024-07-17 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108264520A (zh) * 2017-01-03 2018-07-10 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
JP2018524333A (ja) * 2015-07-02 2018-08-30 ヤンセン・サイエンシズ・アイルランド・ユーシー 環化スルファモイルアリールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用
WO2019011323A1 (zh) * 2017-07-14 2019-01-17 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524333A (ja) * 2015-07-02 2018-08-30 ヤンセン・サイエンシズ・アイルランド・ユーシー 環化スルファモイルアリールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用
CN108264520A (zh) * 2017-01-03 2018-07-10 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
WO2019011323A1 (zh) * 2017-07-14 2019-01-17 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
CN113423712A (zh) 2021-09-21
BR112021015864A2 (pt) 2021-10-05
EP3924357A1 (en) 2021-12-22
EP3924357A4 (en) 2023-02-22
TW202045516A (zh) 2020-12-16
US20200345749A1 (en) 2020-11-05
SG11202108835SA (en) 2021-09-29
CA3128061A1 (en) 2020-08-20
MX2021009717A (es) 2021-09-14
WO2020167984A1 (en) 2020-08-20
IL284940A (en) 2021-09-30
KR20210126636A (ko) 2021-10-20
AU2020221839A1 (en) 2021-08-19
US11033556B2 (en) 2021-06-15
AU2020221839B2 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
KR102323515B1 (ko) 아자-피리돈 화합물 및 이의 용도
JP7710215B2 (ja) ピロール化合物
JP5615902B2 (ja) イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
WO2015038660A1 (en) Pyridazinone compounds and uses thereof
US11136321B2 (en) Tricyclic compounds
CA3197470A1 (en) Bicyclic compounds
JP2022519764A (ja) 二環式スルホンアミド
US20220000874A1 (en) Tricyclic compounds
WO2023205645A1 (en) Bicyclic compounds
CN110857298A (zh) 杂芳基并四氢吡啶类化合物、包含其的药物组合物、其制备方法及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231012